Literature DB >> 2711906

[Intraoperative radiotherapy in locally advanced carcinoma of the kidney: initial experience].

M Santos, A Ucar, H Ramos, L Escudé, J M Berian, J Zudaire, F A Calvo.   

Abstract

Intraoperative radiotherapy (IORT) is a rather interesting therapeutic modality in multidisciplinary oncology. Its greatest advantages reside in the approach of deeply seeded abdomino-pelvic tumors. Its inclusion in the therapeutic approach of renal carcinoma with a high local relapse rate has been analyzed in this study in relation to its technical aspects and preliminary clinical results. 11 stage III or IV patients or with local relapse in lumbar fossa were treated with nephrectomy or exeresis surgery and OIRT (10-20 Gy). Surgical exposure of the lumbar fossa and nodal drainage areas was appropriate in dal cases. No toxic signs or sequellae relating to OIRT were observed. Local tumor controls at 8 months of follow-up on the average (range from 2 to 33 months), was 82%. The data obtained in this series suggest the viability of the combined approach nephrectomy or rescue surgery and IORT. The initial clinical results suggest HIGH local tumor control without an increase in the toxicity rate or complications.

Entities:  

Mesh:

Year:  1989        PMID: 2711906

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  3 in total

Review 1.  Surgery for metastatic renal cell cancer.

Authors:  Shomik Sengupta; Bradley C Leibovich; Michael L Blute; Horst Zincke
Journal:  World J Urol       Date:  2005-06-30       Impact factor: 4.226

2.  Intraoperative EBRT and resection for renal cell carcinoma : twenty-year outcomes.

Authors:  F A Calvo; C V Sole; R Martinez-Monge; I Azinovic; J Aristu; J Zudaire; J L Garcia-Sabrido; J M Berian
Journal:  Strahlenther Onkol       Date:  2012-12-09       Impact factor: 3.621

3.  Intraoperative electron radiation therapy (IOERT) in patients with locally recurrent renal cell carcinoma.

Authors:  Gregor Habl; Matthias Uhl; Frank Hensley; Sascha Pahernik; Juergen Debus; Falk Röder
Journal:  Radiat Oncol       Date:  2013-12-02       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.